Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, this improvement lasted for up to 140 days after the single dose.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a proof-of-concept study with a single application of the anti-IL-33 antibody etokimab (ANB020) in 12 patients with moderate or severe AD, 33% of patients reached the primary end point EASI75 and 83% reached EASI50 (ref.68).”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Etokimab inhibited direct, as well as CXCR1-dependent, neutrophil migration in vitro.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundSelf-citationγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731 · cited 1×
“In murine models, either IL-33 or TSLP alone is sufficient to promote the development of AD-like inflammation (39).”
BackgroundSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G
Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.-P., & Cayrol, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115884109 · Cited by 594 · cited 1×
“Furthermore, IL-33 can be cleaved into active forms by neutrophil elastase and cathepsin G (21), implicating an inflammatory cycle.”
BackgroundThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546 · cited 1×
“The soluble IL-33 decoy receptor soluble ST2 (sST2) has been used in treating allergic diseases in model systems (27).”
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350
Cayrol, C., & Girard, J.-P. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155891 · Cited by 322
Role of IL‐25, IL‐33, and TSLP in triggering united airway diseases toward type 2 inflammation
Hong, H., Liao, S., Chen, F., Yang, Q., & Wang, D. (2020) · Allergy · doi:10.1111/all.14526 · Cited by 272
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277
“ANB020 (Etokimab) and REGN3500 A phase II clinical trial of ANB020 (etokimab), an anti-IL-33 monoclonal antibody, is ongoing (NCT03533751).”
MethodBrough, H. A., Nadeau, K. C., Sindher, S. B., Alkotob, S. S., Chan, S., Bahnson, H. T., Leung, D. Y. M., & Lack, G. (2020) · Allergy · doi:10.1111/all.14304 · Cited by 275
Keratinocytes: innate immune cells in atopic dermatitis
Chieosilapatham, P., Kiatsurayanon, C., Umehara, Y., Trujillo-Paez, J. V., Peng, G., Yue, H., Nguyen, L. T. H., & Niyonsaba, F. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13575 · Cited by 217
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 198
Furue, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113741 · Cited by 168
Emerging Functions of IL-33 in Homeostasis and Immunity
Dwyer, G. K., D’Cruz, L. M., & Turnquist, H. R. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-124243 · Cited by 180
TSLP, IL-33, and IL-25: Not just for allergy and helminth infection
Stanbery, A. G., Smita, S., von Moltke, J., Wojno, E. D. T., & Ziegler, S. F. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.07.003 · Cited by 151
IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain
Yin, C., Liu, B., Li, Y., Li, X., Wang, J., Chen, R., Tai, Y., Shou, Q., Wang, P., Shao, X., et al. (2020) · Theranostics · doi:10.7150/thno.48028 · Cited by 142
Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., & Madonna, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052684 · Cited by 128
Itch: A Paradigm of Neuroimmune Crosstalk
Wang, F., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.008 · Cited by 129
Heterogeneity in the initiation, development and function of type 2 immunity
Gause, W. C., Rothlin, C., & Loke, P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0301-x · Cited by 119
Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s
Bartemes, K. R., & Kita, H. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.015 · Cited by 127
Qiu, Z., Zhu, Z., Liu, X., Chen, B., Yin, H., Gu, C., Fang, X., Zhu, R., Yu, T., Mi, W., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212397 · Cited by 105
“Drugs targeting IL-33 have already been used to treat several diseases and have demonstrated high efficacy (Chen et al., 2019).”
The Role of Type 2 Innate Lymphoid Cells in Allergic Diseases
Zheng, H., Zhang, Y., Pan, J., Liu, N., Qin, Y., Qiu, L., Liu, M., & Wang, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.586078 · Cited by 109
“A clinical trial on etokimab, an IL-33 antibody, for the treatment of AD also revealed the vital role of IL-33 in mediating human AD (125).”
BackgroundCurrent Insights into Immunology and Novel Therapeutics of Atopic Dermatitis
Kader, H. A., Azeem, M., Jwayed, S. A., Al-Shehhi, A., Tabassum, A., Ayoub, M. A., Hetta, H. F., Waheed, Y., Iratni, R., Aldhaheri, A., et al. (2021) · Cells · doi:10.3390/cells10061392 · Cited by 105
Keratinocytes: An Enigmatic Factor in Atopic Dermatitis
Das, P., Mounika, P., Yellurkar, M. L., Prasanna, V. S., Sarkar, S., Ravichandiran, V., & Arumugam, S. (2022) · Cells · doi:10.3390/cells11101683 · Cited by 106
“Etokimab was found to inhibit the migration of neutrophils in vitro, either directly or via CXCR-1 [101].”
BackgroundChallenges and Future Trends in Atopic Dermatitis
Gatmaitan, J. G., & Lee, J. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411380 · Cited by 110
Tissue-specific immunity in helminth infections
Vacca, F., & Le Gros, G. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00531-w · Cited by 86
From Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 93
Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets
Racca, F., Pellegatta, G., Cataldo, G., Vespa, E., Carlani, E., Pelaia, C., Paoletti, G., Messina, M., Nappi, E., Canonica, G. W., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.815842 · Cited by 91
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33
Al Kindi, A., Williams, H., Matsuda, K., Alkahtani, A. M., Saville, C., Bennett, H., Alshammari, Y., Tan, S. Y., O’Neill, C., Tanaka, A., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.023 · Cited by 73
Curren, B. F., Ahmed, T., Howard, D. R., Ullah, M. A., Sebina, I., Rashid, R. B., Sikder, M. A. A., Namubiru, P., Bissell, A., Ngo, S., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.07.002 · Cited by 76
Maurer, M., Cheung, D. S., Theess, W., Yang, X., Dolton, M. J., Guttman, A., Choy, D. F., Dash, A., Grimbaldeston, M. A., & Soong, W. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.015 · Cited by 74
Yazıcı, D., Öğülür, İ., Pat, Y., Babayev, H., Barletta, E., Ardıçlı, S., Imam, M. B., Huang, M., Koch, J., Li, M., et al. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101846 · Cited by 82
Yamamura, Y., Nakashima, C., & Otsuka, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1342176 · Cited by 99
Calabrese, L., Fiocco, Z., Satoh, T. K., Peris, K., & French, L. E. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20975 · Cited by 75
Georgakis, S., Gkirtzimanaki, K., Papadaki, G., Gakiopoulou, H., Drakos, E., Eloranta, M., Makridakis, M., Kontostathi, G., Zoidakis, J., Baira, E., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147671 · Cited by 73
“Anti–IL-33 and/or aST2L antibodies are currently under clinical development (72); in a preliminary report, administration of anti–IL-33 antibody in MRL/lpr lupus–prone mice reduced anti-dsDNA and IC levels, kidney inflammation, and proteinuria (31).”
BackgroundBiologics in Asthma: A Molecular Perspective to Precision Medicine
Salter, B., Lacy, P., & Mukherjee, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.793409 · Cited by 76
“Etokimab has been shown to improve symptoms related to atopic dermatitis and reduce desensitization to peanuts (Chen et al., 2019; Chinthrajah et al., 2019).”
BackgroundThe IL-1 cytokine family as custodians of barrier immunity
Matarazzo, L., Hernandez-Santana, Y., Walsh, P. T., & Fallon, P. G. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155890 · Cited by 71
IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential
Sheng, F., Mi, L., Yu, J.-M., Yang, S., Zou, L., Yang, G., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533335 · Cited by 74
Iznardo, H., & Puig, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169479 · Cited by 69
Endotypes of atopic dermatitis
Fyhrquist, N., Yang, Y., Karisola, P., & Alenius, H. T. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.029 · Cited by 79
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Targeting alarmins in asthma: From bench to clinic
Akenroye, A. T., Boyce, J. A., & Kita, H. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.01.017 · Cited by 67
Immunosensation: Neuroimmune Cross Talk in the Skin
Tamari, M., Heul, A. V., & Kim, B. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101719-113805 · Cited by 64
IL‐33/ST2 as a potential target for tumor immunotherapy
Jiang, W., Lian, J., Yue, Y., & Zhang, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202149175 · Cited by 61
The MRGPR family of receptors in immunity
Gour, N., & Dong, X. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.012 · Cited by 62
“68, 69 Thus, it is reasonable to foresee that allergens can engage two different mechanisms: 1) via a cysteine protease-dependent nociceptor-mast cells module and 2) through a serine protease-induced IL-33 axis, both converging in driving the development of type 2 immunity in AD.”
BackgroundEosinophilic esophagitis: Immune mechanisms and therapeutic targets
Khokhar, D. S., Marella, S., Idelman, G., Chang, J. W., Chehade, M., & Hogan, S. P. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14196 · Cited by 65
The IL-1 family in tumorigenesis and antitumor immunity
Sun, R., Gao, D. S., Shoush, J., & Lu, B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.002 · Cited by 63
Biological Therapies for Atopic Dermatitis: A Systematic Review
Zhou, S., Qi, F., Gong, Y., Zhang, J., & Zhu, B. (2021) · Dermatology · doi:10.1159/000514535 · Cited by 52
Pareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., & Chuturgoon, A. A. (2024) · Cells · doi:10.3390/cells13050425 · Cited by 69
“A single application of Etokimab was administered in a proof-of-concept study using 12 patients, and the improvement was observed to last for 140 days [60].”
MethodNovel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans
Nakajima, S., Tie, D., Nomura, T., & Kabashima, K. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155664 · Cited by 62
Interleukin (IL)‐33: an orchestrator of immunity from host defence to tissue homeostasis
Zhou, Z., Yan, F., & Liu, O. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1146 · Cited by 56
“Strikingly, etokimab, an anti-IL-33humanised monoclonal antibody, has undergone a randomised phase 2a clinical trial in the treatment of patients with moderate-to-severe AD and has shown promising efficacy.(88)”
BackgroundGroup 2 innate lymphoid cells in nasal polyposis
Stevens, W. W., & Kato, A. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.08.001 · Cited by 53
Atopic dermatitis: pathogenesis and therapeutic intervention
Yue, C., Zhou, H., Wang, X., Yu, J., Hu, Y., Zhou, P., Zhao, F., Zeng, F., Li, G., Li, Y., et al. (2024) · MedComm · doi:10.1002/mco2.70029 · Cited by 64
Agache, I. O., Akdiş, C. A., Akdiş, M., Brockow, K., Chivato, T., Giacco, S. D., Eiwegger, T., Eyerich, K., Giménez‐Arnau, A. M., Gutermuth, J., et al. (2020) · Allergy · doi:10.1111/all.14690 · Cited by 56
Self-citationIRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
Lavazais, S., Jargosch, M., Dupont, S., Labéguère, F., Menet, C. J., Jagerschmidt, C., Ohm, F., Kupcsik, L., Parent, I., Cottereaux, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abj3289 · Cited by 51
Maintz, L., Bieber, T. R. M., Simpson, H. D., & Demessant‐Flavigny, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060893 · Cited by 61
Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics
Bai, R., Zheng, Y., & Dai, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00313-3 · Cited by 59
“Etokimab blocks IL-33 and its efficacy has been confirmed in a proof-of-concept clinical trial [172].”
Massironi, S., Mulinacci, G., Gallo, C., Elvevi, A., Danese, S., Invernizzi, P., & Vespa, E. (2023) · Cells · doi:10.3390/cells12202473 · Cited by 48
“Etokimab [176] and astegolimab [177], both monoclonal antibodies that selectively inhibit the IL-33–ST2 axis, are expected to show promising results in EoE therapy.”
BackgroundMRGPRX2 sensing of cationic compounds—A bridge between nociception and skin diseases?
Corbière, A., Loste, A., & Gaudenzio, N. (2020) · Experimental Dermatology · doi:10.1111/exd.14222 · Cited by 49
Efficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
“The most common TEAEs were nervous system disorders and infections, occurring in 33% of the patients [111].”
BackgroundInfluentialXu, L., Wei, C., Chen, Y., Wu, Y., Shou, X., Chen, W., Lu, D., Sun, H., Li, W., Yu, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34660-4 · Cited by 49
Self-citationAbdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
“These findings suggest that suppressing IL-31 may be an additional part of AD therapy and may have a favorable impact on inflammatory responses (Chen et al. 2019).”
IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies
Donovan, C., & Hansbro, P. M. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00099 · Cited by 46
IL33 and Mast Cells—The Key Regulators of Immune Responses in Gastrointestinal Cancers?
Eissmann, M. F., Büchert, M., & Ernst, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01389 · Cited by 49
“AMG 282, RG6149 Amgen NCT03747575 2 Atopic dermatitis Active, not recruiting (anti-ST2) REGN3500, Sanofi/Regeneron NCT03387852 2 asthma Completed, met 1st & 2nd endpoint SAR440340 NCT03546907 2 COPD* Recruitment completed (anti-IL33) NCT03736967 2 Atopic dermatitis Recruiting NCT03738423 GSK3772847, GSK/ NCT03207243 2…”
Achieving Precision Medicine in Allergic Disease: Progress and Challenges
Proper, S. P., Azouz, N. P., & Baye, T. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720746 · Cited by 51
“One method less invasive than biopsy showing promise in immunophenotyping of skin is creation of suction (negative pressure) blisters and sampling the resulting blister fluid and the blister roof of epidermal cells (36).”
MethodIL-33: A central cytokine in helminth infections
McSorley, H. J., & Smyth, D. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101532 · Cited by 47
“development to treat allergic disease [148-150].”
Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes
Florens, N., Kasam, R. K., Rudman-Melnick, V., Lin, S. J., Prasad, V., & Molkentin, J. D. (2023) · Circulation · doi:10.1161/circulationaha.122.063014 · Cited by 42
Yang, X., Kambe, N., Takimoto‐Ito, R., & Kabashima, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107830 · Cited by 45
Wang, Z., Pan, B., Qiu, J., Zhang, X., Ke, X., Shen, S., Wu, X., Yao, Y., & Tang, N. (2023) · Science Signaling · doi:10.1126/scisignal.abq3362 · Cited by 49
Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives
Kahremany, S., Hofmann, L., Harari, M., Gruzman, A., & Cohen, G. (2021) · Pharmacological Reports · doi:10.1007/s43440-020-00206-y · Cited by 41
ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses
Forster, P. M., Rompe, Z. A., Jakob, M. O., Stamm, A., Leclère, P. S., Preußer, A., Duerr, C. U., Thole, L. M. L., Kotsch, K., Artis, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130933 · Cited by 44
Jeseňák, M., Diamant, Z., Simon, D., Tufvesson, E., Seys, S., Mukherjee, M., Lacy, P., Vijverberg, S. J. H., Slisz, T., Šedivá, A., et al. (2023) · Allergy · doi:10.1111/all.15884 · Cited by 39
The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases
Topal, F. A., Zuberbier, T., Makris, M. P., & Hofmann, M. A. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000658 · Cited by 38
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis
Yang, N., Chen, Z., Zhang, X., & Shi, Y. (2021) · BioDrugs · doi:10.1007/s40259-021-00490-x · Cited by 39
Warren, K. J., Poole, J. A., Sweeter, J. M., DeVasure, J. M., Dickinson, J. D., Peebles, R. S., & Wyatt, T. A. (2021) · Respiratory Research · doi:10.1186/s12931-021-01799-5 · Cited by 36
Tissue-Dependent Adaptations and Functions of Innate Lymphoid Cells
Murphy, J. M., Ngai, L., Mortha, A., & Crome, S. Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836999 · Cited by 40
The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis
Wong, L., Yen, Y.-T., & Lee, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137227 · Cited by 36
“Improvements in the DLQI and 5D itch scales were also significant [13].”
BackgroundBarrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective
Ghezzi, M., Pozzi, E., Abbattista, L., Lonoce, L., Zuccotti, G., & D’Auria, E. (2021) · Children · doi:10.3390/children8121165 · Cited by 39
Cytokines and chemokines modulation of itch.
Du, L.-X., Zhu, J.-Y., & Mi, W. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.035 · Cited by 16
Whole blood stimulation as a tool for studying the human immune system
Müller, S. M., Kröger, C., Schultze, J. L., & Aschenbrenner, A. C. (2023) · European Journal of Immunology · doi:10.1002/eji.202350519 · Cited by 40
“For example, in a phase 2a trial a single dose of etokimab, an anti-IL33 antibody, was shown to strongly inhibit IFN-γ release after ex vivo IL12/IL33 stimulation in patients with moderate to severe atopic dermatitis 57 days after etokimab injection [84].”
BackgroundNeutrophils in Atopic Dermatitis
Chiang, C.-C., Cheng, W.-J., Cruz, J. R. M. S. D., Raviraj, T., Wu, N., Kořínek, M., & Hwang, T. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-09004-3 · Cited by 40
Impact of a Decade of Research Into Atopic Dermatitis
Arkwright, P. D., & Koplin, J. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.021 · Cited by 35
The role of interleukin-33 in organ fibrosis
Carmine, S. D., Scott, M. M., McLean, M. H., & McSorley, H. J. (2022) · Discovery Immunology · doi:10.1093/discim/kyac006 · Cited by 36
Th2A cells: The pathogenic players in allergic diseases
Huang, Z., Chu, M., Chen, X., Wang, Z., Lin, J., Ma, Y., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.916778 · Cited by 38
“IL-33 Etokimab (ANB020) AD, asthma, peanut allergy Phase 2 (102)”
BackgroundFukuda, K., Kishimoto, T., Sumi, T., Yamashiro, K., & Ebihara, N. (2022) · Allergology International · doi:10.1016/j.alit.2022.09.005 · Cited by 33
A Truncated Form of HpARI Stabilizes IL-33, Amplifying Responses to the Cytokine
Chauché, C., Vacca, F., Chia, S. L., Richards, J., Gregory, W. F., Ogunkanbi, A., Wear, M. A., & McSorley, H. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01363 · Cited by 29
“As anti-IL-33 treatments enter clinical trials (37), this is an important consideration, as suboptimal antibodies could result in amplification rather than suppression of IL-33 responses.”
BackgroundThe pathology of type 2 inflammation-associated itch in atopic dermatitis
Moniaga, C. S., Tominaga, M., & Takamori, K. (2021) · Diagnostics · doi:10.3390/diagnostics11112090 · Cited by 28
Therapeutic New Era for Atopic Dermatitis: Part 1. Biologics
Ahn, J., Choi, Y. S., & Simpson, E. L. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.1.1 · Cited by 30
Radi, G., Campanati, A., Diotallevi, F., Martina, E., Marani, A., & Offidani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10112700 · Cited by 31
Rothenberg‐Lausell, C., Bar, J., Dahabreh, D., Renert‐Yuval, Y., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.04.009 · Cited by 27
Targeting Mast Cells with Biologics
Lyons, J. J., & Metcalfe, D. D. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.007 · Cited by 28
The New Era of Biologics in Atopic Dermatitis: A Review
Schneider, S., Li, L., & Zink, A. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1104a144 · Cited by 28
“Etokimab IL-31 2b, still recruiting 83% improvement of EASI50 and 33% EASI75 after 29-days of a single dose (Phase IIa) [33]”
BackgroundIL-33 acts as a costimulatory signal to generate alloreactive Th1 cells in graft-versus-host disease
Dwyer, G. K., Mathews, L. R., Villegas, J. A., Lucas, A., de Peredo, A. G., Blazar, B. R., Girard, J., Poholek, A. C., Luther, S. A., Shlomchik, W. D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150927 · Cited by 27
“This finding suggests that the combined targeting of IL-33 and IL-12 using antibodies undergoing clinical testing (87, 88) immediately after alloHCT would target 2 distinct Th1-driving pathways and thus be highly effective in limiting early donor Th1 responses.”
Parrón‐Ballesteros, J., Gordo, R. G., López‐Rodríguez, J. C., Olmo, N., Villalba, M., Batanero, E., & Turnay, J. (2023) · Frontiers in Allergy · doi:10.3389/falgy.2023.1093800 · Cited by 26
Uppal, S. K., Kearns, D. G., Chat, V. S., Han, G., & Wu, J. J. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1775775 · Cited by 27
Epithelial barrier regulation, antigen sampling, and food allergy
Cook‐Mills, J. M., & Emmerson, L. N. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.06.018 · Cited by 26
Biologics for Atopic Dermatitis
Boguniewicz, M. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.004 · Cited by 24
Cutaneous neuroimmune crosstalk in pruritus
Agelopoulos, K., Pereira, M. P., Wiegmann, H., & Ständer, S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.005 · Cited by 30
The Dawn of a New Era in Atopic Dermatitis Treatment
Yamamura, K., & Nakahara, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206145 · Cited by 27
Metadata
- Authors
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G.
- Affiliations
- University of Oxford (GB)
- MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
- AnaptysBio, Inc. (United States) (US)
- Corresponding author
- Ogg, Graham
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-10-23
- Volume
- 11
- Issue
- 515
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2979421310
- Cited by
- 250
- References
- 46
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 38 · 2023: 31 · 2022: 48 · 2021: 50 · 2020: 37 · 2019: 1
- FWCI
- 34.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MCUU_0008/5)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, neutrophil migration, CXCR1, interleukin-8, eosinophils, skin inflammation, Eczema Area and Severity Index
- MeSH terms
- Interleukin-33, Antibodies, Monoclonal, Cell Movement, Dermatitis, Atopic, Eczema, Humans, Inflammation, Neutrophils, Skin, Interleukin-12, Receptors, Interleukin-8A, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.